Products - Blood and bone marrow cancers | Topic | NICE

Showing 229 products

Date | Title

Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 April 2021
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over TSID 12036
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 August 2022
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA872)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 February 2023
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (TA895)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 June 2023
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 June 2023
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 March 2011
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 July 2016
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 March 2025
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
19 March 2025
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 February 2024
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 February 2011
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) (TA206)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 October 2010
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2017
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA686)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 March 2021
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 July 2019
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 March 2025
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 July 2011
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 April 2014
Bortezomib for previously untreated mantle cell lymphoma (TA370)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2015
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) (TA453)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 July 2017
Bortezomib monotherapy for relapsed multiple myeloma (TA129)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 October 2007
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) (TA576)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 April 2019
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 April 2019
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 October 2017
Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 August 2019
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 August 2020
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
28 January 2025
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma ID 6437
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over (TA893)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 June 2023
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 February 2021
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments [ID6325](review of TA677)
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 September 2025
Carfilzomib for previously treated multiple myeloma (TA657)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 November 2020
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA841)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 November 2022
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 April 2021
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 August 2021
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA889)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 May 2023
clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia (MIB278)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
30 November 2021
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 April 2022
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 June 2023
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) (TA771)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 February 2022
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA454)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 July 2017
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA634)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 June 2020
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (TA917)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 October 2023
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA726)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 September 2021
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
28 July 2021
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA714)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 July 2021
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 December 2016
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 December 2016
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) (TA932)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 November 2023
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) (TA270)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 December 2012
Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 December 2018
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 December 2018
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) (TA717)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 July 2021
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) (TA811)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 July 2022
Elotuzumab for previously treated multiple myeloma (terminated appraisal) (TA434)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 March 2017
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 December 2024
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 March 2024
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID 6463
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epcoritamab for treating relapsed or refractory follicular lymphoma ID6338
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 November 2024
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2021
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 February 2007
Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) (DG47)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
30 March 2022
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 November 2018
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 August 2020
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) (TA646)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 September 2020
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 October 2023
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 September 2001
Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 January 2016
Published:
22 October 2003
Haematological cancers (QS150)
Product type:
Quality standard
Published:
1 June 2017
Haematological cancers: improving outcomes (NG47)
Product type:
Guidance
Programme:
NICE guideline
Published:
25 May 2016
High intensity focused ultrasound ablation for pain caused by bone metastases
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [ID6455]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia TSID 12043
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 January 2017
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 January 2018
Ibrutinib for treating Waldenstrom’s macroglobulinaemia (TA795)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 June 2022
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) (TA452)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 July 2017
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) (TA437)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 March 2017
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) (TA702)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 May 2021
Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal) (TA608)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 October 2019
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) (TA703)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 May 2021
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 May 2023
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) (TA936)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 November 2023
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Idelalisib for treating chronic lymphocytic leukaemia (TA359)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 October 2015
Idelalisib for treating refractory follicular lymphoma (TA604)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 October 2019
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) (TA469)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 August 2017
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor TS ID 8376
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 September 2018
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
16 July 2025
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA727)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 September 2021
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 November 2020
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 June 2024
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA870)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 February 2023
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA774)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 March 2022
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies (TA171)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
26 June 2019
Published:
18 June 2009
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
26 June 2019
Published:
24 September 2014
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 March 2021
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 June 2019
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 June 2019
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 September 2019
Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 April 2020
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 December 2018
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) (TA987)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 July 2024
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable [ID3887]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
5 December 2024
Expected publication date:
TBC
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments (TA947)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 January 2024
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA968)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 April 2024
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) (TA822)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 September 2022
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment TS ID 12121
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Midostaurin for untreated acute myeloid leukaemia (TA523)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Mifamurtide for the treatment of osteosarcoma (TA235)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 October 2011
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
10 August 2021
MMprofiler for prognostic risk classification in multiple myeloma (MT623) (MIB270)
Status:
Topic selection
Programme:
Diagnostics guidance
Expected publication date:
TBC
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 December 2021
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2024
Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 May 2023
Myeloma: diagnosis and management (NG35)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
25 October 2018
Published:
10 February 2016
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 July 2017
Non-Hodgkin’s lymphoma: diagnosis and management (NG52)
Product type:
Guidance
Programme:
NICE guideline
Published:
20 July 2016
Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)
Product type:
Advice
Programme:
Evidence summary
Published:
9 September 2014
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 March 2018
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 June 2015
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 May 2020
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 October 2022
Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2016
Pegaspargase for treating acute lymphoblastic leukaemia (TA408)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 May 2024
Published:
3 September 2018
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies (TA772)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 February 2022
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 May 2024
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor ID 6493
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma (TA306)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 February 2014
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 March 2023
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 September 2020
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 January 2017
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA602)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 September 2019
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2017
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (TA1013)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 October 2024
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Resminostat for maintenance treatment of advanced mycosis fungoides or Sézary syndrome ID6478
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (TA226)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2011
Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2009
Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 January 2012
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 July 2010
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (TA137)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 February 2008
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
29 January 2025
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) (TA839)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 November 2022
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal) (TA840)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 November 2022
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 May 2024
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (TA970)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 May 2024
Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments TSID 11969
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published:
30 June 2016
Suspected cancer: recognition and referral (NG12)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 October 2023
Published:
23 June 2015
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (TA883)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 May 2023
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) (TA782)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 March 2022
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments ID5082
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 November 2024
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA207)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 October 2010
The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
12 February 2015
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) (TA842)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 November 2022
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 May 2024
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) (TA933)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 November 2023
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 August 2020
Venetoclax for treating chronic lymphocytic leukaemia (TA796)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 June 2022
Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant ID 6468
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2022
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 December 2020
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 February 2019
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 November 2023
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 September 2024
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Zanubrutinib for treating Waldenstrom’s macroglobulinaemia (TA833)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 October 2022
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) (TA978)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 May 2024